

Ian Reid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/488820/publications.pdf>

Version: 2024-02-01

423
papers

38,762
citations

2213

99
h-index

3181

186
g-index

445
all docs

445
docs citations

445
times ranked

23701
citing authors

#	ARTICLE	IF	CITATIONS
1	Dietary calcium intake and change in bone mineral density in older adults: a systematic review of longitudinal cohort studies. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 196-205.	1.3	14
2	Bone-friendly lifestyle and the role of calcium or vitamin D supplementation. <i>Climacteric</i> , 2022, 25, 37-42.	1.1	3
3	Drug therapy for osteoporosis in older adults. <i>Lancet, The</i> , 2022, 399, 1080-1092.	6.3	193
4	How Often Should We Measure Bone Density?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e4267-e4268.	1.8	1
5	Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. <i>Journal of Clinical Densitometry</i> , 2021, 24, 3-13.	0.5	35
6	Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region. <i>Osteoporosis International</i> , 2021, 32, 1249-1275.	1.3	28
7	Molecular characterisation of osteoblasts from bone obtained from people of Polynesian and European ancestry undergoing joint replacement surgery. <i>Scientific Reports</i> , 2021, 11, 2428.	1.6	2
8	Bisphosphonate holidays. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 35-36.	0.3	3
9	Effect of Zoledronate on Lower Respiratory Infections in Older Women: Secondary Analysis of a Randomized Controlled Trial. <i>Calcified Tissue International</i> , 2021, 109, 12-16.	1.5	11
10	Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women. <i>Arthritis and Rheumatology</i> , 2021, 73, 1758-1764.	2.9	5
11	Stopping osteoporosis medications. <i>Journal of Internal Medicine</i> , 2021, 290, 1102-1104.	2.7	2
12	Revisiting osteoporosis guidelines. <i>Lancet Diabetes and Endocrinology,the</i> , 2021, 9, 805-806.	5.5	7
13	Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 20-27.	3.1	63
14	Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial. <i>Calcified Tissue International</i> , 2020, 106, 386-391.	1.5	5
15	Management of Paget's disease of bone. <i>Osteoporosis International</i> , 2020, 31, 827-837.	1.3	12
16	No more fracture trials in osteoporosis?. <i>Lancet Diabetes and Endocrinology,the</i> , 2020, 8, 650-651.	5.5	3
17	Benefits of Bisphosphonate Therapy: Beyond the Skeleton. <i>Current Osteoporosis Reports</i> , 2020, 18, 587-596.	1.5	20
18	A prediction tool for vitamin D deficiency in New Zealand adults. <i>Archives of Osteoporosis</i> , 2020, 15, 172.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1040-1047.	3.1	6
20	The effect of age on the microarchitecture and profile of gene expression in femoral head and neck bone from patients with osteoarthritis. <i>Bone Reports</i> , 2020, 13, 100287.	0.2	2
21	A broader strategy for osteoporosis interventions. <i>Nature Reviews Endocrinology</i> , 2020, 16, 333-339.	4.3	132
22	Osteoporosis: evidence for vitamin D and calcium in older people. <i>Drug and Therapeutics Bulletin</i> , 2020, 58, 122-125.	0.3	10
23	Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1641-e1647.	1.8	28
24	Zoledronate. <i>Bone</i> , 2020, 137, 115390.	1.4	39
25	What factors modify the effect of monthly bolus dose vitamin D supplementation on 25-hydroxyvitamin D concentrations?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 201, 105687.	1.2	16
26	Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 996-997.	3.1	3
27	Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It?. <i>Nutrients</i> , 2020, 12, 1011.	1.7	43
28	Predictors of Fracture in Older Women With Osteopenic Hip Bone Mineral Density Treated With Zoledronate. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 61-66.	3.1	8
29	Monitoring Osteoporosis Therapy. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1423-1424.	3.1	1
30	The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 21-28.	3.1	12
31	Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 3-11.	3.1	14
32	Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1437-1445.	3.1	28
33	Pathogenesis of Osteoporosis. , 2019, , 222-232.		2
34	Bisphosphonates for Prevention of Bone Loss in Glucocorticoid-Treated Young People. <i>EClinicalMedicine</i> , 2019, 12, 8-9.	3.2	2
35	Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells. <i>Calcified Tissue International</i> , 2019, 105, 497-505.	1.5	7
36	Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. <i>Calcified Tissue International</i> , 2019, 105, 423-429.	1.5	3

#	ARTICLE	IF	CITATIONS
37	Controversies in medicine: the role of calcium and vitamin D supplements in adults. Medical Journal of Australia, 2019, 211, 468-473.	0.8	43
38	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes and Endocrinology, 2019, 7, 899-911.	5.5	111
39	Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up. Calcified Tissue International, 2019, 105, 107-108.	1.5	19
40	Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. Journal of Internal Medicine, 2019, 286, 221-229.	2.7	21
41	Dietary Calcium Intake and Bone Loss Over 6 Years in Osteopenic Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3576-3584.	1.8	23
42	Fibroblast growth factor 23 levels decline following sleeve gastrectomy. Clinical Endocrinology, 2019, 91, 87-93.	1.2	6
43	Osteomalacia in subtropical Auckland. BMJ Case Reports, 2019, 12, e229657.	0.2	2
44	Calcium and Bone. Handbook of Experimental Pharmacology, 2019, 262, 259-280.	0.9	5
45	Longitudinal changes in bone mineral density, bone mineral content and bone area at the lumbar spine and hip in postmenopausal women, and the influence of abdominal aortic calcification. Bone Reports, 2019, 10, 100190.	0.2	6
46	Recent advances in understanding and managing Paget's disease. F1000Research, 2019, 8, 1485.	0.8	2
47	25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial. Journal of Bone and Mineral Research, 2018, 33, 1464-1469.	3.1	92
48	Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates. Calcified Tissue International, 2018, 103, 55-61.	1.5	76
49	Lack of Evidence that Soluble Urate Directly Influences Bone Remodelling: A Laboratory and Clinical Study. Calcified Tissue International, 2018, 102, 73-84.	1.5	4
50	Effects of Leptin on the Skeleton. Endocrine Reviews, 2018, 39, 938-959.	8.9	107
51	Fracture Prevention with Zoledronate in Older Women with Osteopenia. New England Journal of Medicine, 2018, 379, 2407-2416.	13.9	280
52	High-dose vitamin D: Without benefit but not without risk. Journal of Internal Medicine, 2018, 284, 694-696.	2.7	5
53	Denosumab for glucocorticoid-induced osteoporosis. Nature Reviews Endocrinology, 2018, 14, 383-384.	4.3	5
54	Calcium and vitamin D do not prevent fractures in community-dwelling adults. BMJ Evidence-Based Medicine, 2018, 23, 185-186.	1.7	0

#	ARTICLE	IF	CITATIONS
55	Calcium and vitamin D: To supplement or not?. Cleveland Clinic Journal of Medicine, 2018, 85, 693-698.	0.6	5
56	Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone. Calcified Tissue International, 2017, 100, 250-254.	1.5	8
57	Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial. Osteoporosis International, 2017, 28, 1867-1874.	1.3	10
58	Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone. Calcified Tissue International, 2017, 101, 43-49.	1.5	9
59	Bone Loss After Denosumab: Only Partial Protection with Zoledronate. Calcified Tissue International, 2017, 101, 371-374.	1.5	95
60	Dietary calcium intake and rate of bone loss in men. British Journal of Nutrition, 2017, 117, 1432-1438.	1.2	14
61	Serum phosphate is related to adiposity in healthy adults. European Journal of Clinical Investigation, 2017, 47, 486-493.	1.7	14
62	Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blososumab. BioDrugs, 2017, 31, 289-297.	2.2	15
63	Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. Journal of Clinical Densitometry, 2017, 20, 8-24.	0.5	185
64	Vitamin D Effect on Bone Mineral Density and Fractures. Endocrinology and Metabolism Clinics of North America, 2017, 46, 935-945.	1.2	55
65	Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. Cmaj, 2017, 189, E1130-E1136.	0.9	34
66	Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial. Journal of Internal Medicine, 2017, 282, 452-460.	2.7	100
67	Are more trials of calcium supplements really needed?. Osteoporosis International, 2017, 28, 2729-2730.	1.3	1
68	Calcium Intake and Cardiovascular Disease Risk. Annals of Internal Medicine, 2017, 166, 684.	2.0	7
69	Durability of Response to Zoledronate Treatment and Competing Mortality in Paget's Disease of Bone. Journal of Bone and Mineral Research, 2017, 32, 753-756.	3.1	33
70	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. Journal of Bone and Mineral Research, 2017, 32, 3-10.	3.1	127
71	Acute effects of calcium supplements on blood pressure: randomised, crossover trial in postmenopausal women. Osteoporosis International, 2017, 28, 119-125.	1.3	8
72	Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention. Osteoporosis International, 2017, 28, 733-734.	1.3	7

#	ARTICLE	IF	CITATIONS
73	Calcium and Cardiovascular Disease. <i>Endocrinology and Metabolism</i> , 2017, 32, 339.	1.3	75
74	Treatment of Paget's Disease of Bone. , 2016, , 119-136.		3
75	Towards a trial-based definition of vitamin D deficiency. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 376-377.	5.5	11
76	Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial. <i>Osteoporosis International</i> , 2016, 27, 1209-1216.	1.3	11
77	Controversies in osteoporosis management. <i>Internal Medicine Journal</i> , 2016, 46, 767-770.	0.5	4
78	Postmenopausal osteoporosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16069.	18.1	462
79	Errors in NOF meta-analyses of calcium and vitamin D supplements. <i>Osteoporosis International</i> , 2016, 27, 2637-2639.	1.3	5
80	Vitamin D supplements do not prevent falls. <i>BMJ</i> , 2016, 353, i3005.	3.0	3
81	Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review. <i>Calcified Tissue International</i> , 2016, 99, 322-325.	1.5	46
82	Circulating calcium concentrations, vascular disease and mortality: a systematic review. <i>Journal of Internal Medicine</i> , 2016, 279, 524-540.	2.7	97
83	Reasons for discrepancies in hip fracture risk estimates using FRAX and Garvan calculators. <i>Maturitas</i> , 2016, 85, 11-18.	1.0	9
84	Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study. <i>Osteoporosis International</i> , 2016, 27, 2099-2107.	1.3	32
85	Path Analysis Identifies Receptor Activator of Nuclear Factor- κ B Ligand, Osteoprotegerin, and Sclerostin as Potential Mediators of the Tophus-bone Erosion Relationship in Gout. <i>Journal of Rheumatology</i> , 2016, 43, 445-449.	1.0	12
86	Calcium fortified foods or supplements for older people?. <i>Maturitas</i> , 2016, 85, 1-4.	1.0	3
87	Relationship Between Changes in Serum Urate and Bone Mineral Density During Treatment with Thiazide Diuretics: Secondary Analysis from a Randomized Controlled Trial. <i>Calcified Tissue International</i> , 2016, 98, 474-478.	1.5	6
88	What diseases are causally linked to vitamin D deficiency?. <i>Archives of Disease in Childhood</i> , 2016, 101, 185-189.	1.0	34
89	Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men. <i>BoneKey Reports</i> , 2016, 5, 852.	2.7	7
90	Acute effects of calcium citrate with or without a meal, calcium-fortified juice and a dairy product meal on serum calcium and phosphate: a randomised cross-over trial. <i>British Journal of Nutrition</i> , 2015, 113, 1585-1594.	1.2	26

#	ARTICLE	IF	CITATIONS
91	Acute effects of calcium supplements on blood pressure and blood coagulation: secondary analysis of a randomised controlled trial in post-menopausal women. <i>British Journal of Nutrition</i> , 2015, 114, 1868-1874.	1.2	31
92	Calcium supplements: benefits and risks. <i>Journal of Internal Medicine</i> , 2015, 278, 354-368.	2.7	101
93	Screening for Vitamin D Deficiency. <i>Annals of Internal Medicine</i> , 2015, 162, 736.	2.0	0
94	Denosumab after 8 years. <i>Osteoporosis International</i> , 2015, 26, 2759-2761.	1.3	8
95	The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2015, 30, 934-944.	3.1	205
96	Effects of vitamin D supplements on bone density. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 91-94.	1.8	21
97	The Effects of Re-challenge in Patients with a History of Acute Anterior Uveitis Following Intravenous Zoledronate. <i>Calcified Tissue International</i> , 2015, 97, 58-61.	1.5	14
98	Bone density is normal and does not change over 2 years in sarcoidosis. <i>Osteoporosis International</i> , 2015, 26, 611-616.	1.3	13
99	Short-term and long-term effects of osteoporosis therapies. <i>Nature Reviews Endocrinology</i> , 2015, 11, 418-428.	4.3	147
100	Calcium intake and bone mineral density: systematic review and meta-analysis. <i>BMJ, The</i> , 2015, 351, h4183.	3.0	272
101	Calcium intake and risk of fracture: systematic review. <i>BMJ, The</i> , 2015, 351, h4580.	3.0	241
102	Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?. <i>Climacteric</i> , 2015, 18, 22-31.	1.1	44
103	Vitamin D Supplements and the Risk of Falls. <i>JAMA Internal Medicine</i> , 2015, 175, 1723.	2.6	4
104	Great strides made but still further to go. <i>Nature Reviews Endocrinology</i> , 2015, 11, 633-634.	4.3	2
105	Efficacy, effectiveness and side effects of medications used to prevent fractures. <i>Journal of Internal Medicine</i> , 2015, 277, 690-706.	2.7	75
106	Cardiovascular Complications of Calcium Supplements. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 494-501.	1.2	30
107	Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 3-23.	3.1	957
108	Calcium Supplements Increase Risk of Myocardial Infarction. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 389-390.	3.1	14

#	ARTICLE	IF	CITATIONS
109	Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 570-574.	3.1	21
110	Skeletal health in adults with HIV infection. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 63-74.	5.5	36
111	Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. <i>Osteoporosis International</i> , 2015, 26, 499-503.	1.3	37
112	Vitamin D: The More We Know, the Less We Know. <i>Clinical Chemistry</i> , 2015, 61, 462-465.	1.5	29
113	Bone density in healthy men after cessation of calcium supplements: 20-month follow-up of a randomized controlled trial. <i>Osteoporosis International</i> , 2015, 26, 173-178.	1.3	1
114	Response to letter by Ralston et al. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, L47-L48.	1.8	1
115	Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access Dataset. <i>PLoS ONE</i> , 2015, 10, e0139975.	1.1	10
116	Response to the letter by Asik M., et al. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, L36-L36.	1.8	0
117	Response to Letter. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, L38-L38.	1.8	1
118	Calcium, phosphate and magnesium. , 2014, , 93-123.		1
119	Metabolic bone disease. , 2014, , 604-635.		15
120	Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer. <i>Annals of Internal Medicine</i> , 2014, 160, 655.	2.0	3
121	Should We Prescribe Calcium Supplements For Osteoporosis Prevention?. <i>Journal of Bone Metabolism</i> , 2014, 21, 21.	0.5	35
122	Response to letter to editor. <i>Osteoporosis International</i> , 2014, 25, 2501-2501.	1.3	0
123	Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal women. <i>British Journal of Nutrition</i> , 2014, 112, 1611-1620.	1.2	42
124	Differences in Overlapping Meta-Analyses of Vitamin D Supplements and Falls. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4265-4272.	1.8	53
125	Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4546-4554.	1.8	109
126	Intervals Between Bone Density Testing. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 389-391.	3.1	6

#	ARTICLE	IF	CITATIONS
127	Paget's Disease of Bone: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4408-4422.	1.8	138
128	Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. <i>Human Molecular Genetics</i> , 2014, 23, 3054-3068.	1.4	90
129	Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 166-172.	3.1	21
130	Benefits of Calcium Supplements Are Too Small for Clinical Equipose to Exist. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1914-1915.	3.1	1
131	Vitamin D supplements and bone mineral density – Authors' reply. <i>Lancet, The</i> , 2014, 383, 1293-1294.	6.3	1
132	Calcium risk – benefit updated – New WHI analyses. <i>Maturitas</i> , 2014, 77, 1-3.	1.0	31
133	The Auckland calcium study: 5-year post-trial follow-up. <i>Osteoporosis International</i> , 2014, 25, 297-304.	1.3	25
134	Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2051-2056.	3.1	56
135	Vitamin D supplementation and falls: a trial sequential meta-analysis. <i>Lancet Diabetes and Endocrinology, the</i> , 2014, 2, 573-580.	5.5	149
136	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. <i>Lancet Diabetes and Endocrinology, the</i> , 2014, 2, 307-320.	5.5	371
137	Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. <i>Human Molecular Genetics</i> , 2014, 23, 1923-1933.	1.4	130
138	Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. <i>Lancet, The</i> , 2014, 383, 146-155.	6.3	497
139	Controversy – cardiovascular effects of calcium supplementation. <i>Nature Reviews Endocrinology</i> , 2014, 10, 641-642.	4.3	4
140	Vitamin D: Present and future. <i>Revista Clinica Espanola</i> , 2014, 214, 383-384.	0.2	1
141	Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1044-1051.	0.5	25
142	Vitamin D and falls – Authors' reply. <i>Lancet Diabetes and Endocrinology, the</i> , 2014, 2, 541.	5.5	0
143	Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?. <i>Osteoporosis International</i> , 2014, 25, 2347-2357.	1.3	43
144	The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. <i>European Journal of Endocrinology</i> , 2014, 170, 255-262.	1.9	37

#	ARTICLE	IF	CITATIONS
145	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 364-365.	5.5	9
146	Vitamin D supplements do not reduce mortality risk. <i>BMJ</i> , 2014, 348, g2860-g2860.	3.0	4
147	Government funding of health research in New Zealand. <i>New Zealand Medical Journal</i> , 2014, 127, 25-30.	0.5	2
148	Translation of research into clinical practice: a case study of calcium supplement prescribing in New Zealand. <i>New Zealand Medical Journal</i> , 2014, 127, 94-101.	0.5	3
149	Calcium supplements and cardiovascular risk in the Women's Health Initiative. <i>Osteoporosis International</i> , 2013, 24, 2371-2372.	1.3	4
150	Testosterone Levels Following Decreases in Serum Osteocalcin. <i>Calcified Tissue International</i> , 2013, 93, 133-136.	1.5	15
151	No Reduction in Circulating Preosteoclasts 18 Months after Treatment with Zoledronate: Analysis from a Randomized Placebo Controlled Trial. <i>Calcified Tissue International</i> , 2013, 92, 1-5.	1.5	4
152	Goal-directed treatment of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 433-438.	3.1	54
153	Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1348-1354.	3.1	109
154	Osteoporosis treatment: Focus on safety. <i>European Journal of Internal Medicine</i> , 2013, 24, 691-697.	1.0	29
155	Skeletal Actions of Fasting-Induced Adipose Factor (FIAF). <i>Endocrinology</i> , 2013, 154, 4685-4694.	1.4	5
156	Comment on Kanis et al.: Pitfalls in the external validation of FRAX. <i>Osteoporosis International</i> , 2013, 24, 389-390.	1.3	9
157	The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. <i>Osteoporosis International</i> , 2013, 24, 349-354.	1.3	20
158	The Incidence of Acute Anterior Uveitis after Intravenous Zoledronate. <i>Ophthalmology</i> , 2013, 120, 773-776.	2.5	54
159	Calcium supplements – vascular risks versus bone benefits?. <i>Nature Reviews Endocrinology</i> , 2013, 9, 255-256.	4.3	0
160	Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials. <i>British Journal of Nutrition</i> , 2013, 110, 1384-1393.	1.2	81
161	Long-chain triazolyl acids as inhibitors of osteoclastogenesis. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 4112-4119.	1.4	3
162	Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 557-563.	1.8	78

#	ARTICLE	IF	CITATIONS
163	Calcium supplements and cardiovascular risk: 5 years on. Therapeutic Advances in Drug Safety, 2013, 4, 199-210.	1.0	55
164	Randomised controlled trial of vitamin D supplementation in sarcoidosis. BMJ Open, 2013, 3, e003562.	0.8	33
165	Subgroup analysis for the risk of cardiovascular disease with calcium supplements. BoneKEy Reports, 2013, 2, 293.	2.7	15
166	Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study. BoneKEy Reports, 2013, 2, 442.	2.7	16
167	Low-dose Fluoride in Postmenopausal Women: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2301-2307.	1.8	20
168	Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial. BMJ Open, 2013, 3, e002334.	0.8	16
169	New insights into ONJ. IBMS BoneKEy, 2013, 10, .	0.1	0
170	What is the appropriate MHRA regulatory response to calcium's increased cardiovascular risk?. BMJ, The, 2013, 346, f3413-f3413.	3.0	1
171	Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis. , 2013, , 1701-1737.		0
172	Observational studiesâ€”just telling us what we want to hear or telling us where we need to look?. Journal of Bone and Mineral Research, 2013, 28, 980-983.	3.1	1
173	An inappropriate response?. BMJ, The, 2013, 346, f942-f942.	3.0	3
174	Cardiovascular Effects of Calcium Supplements. Nutrients, 2013, 5, 2522-2529.	1.7	35
175	Cardiovascular Safety of Calcium Supplements. , 2013, , 365-372.		1
176	Relationships Between Body Fat and Bone Mass. , 2013, , 83-92.		1
177	Calcium and cardiovascular risks. Australian Prescriber, 2013, 36, 5-8.	0.5	7
178	All people should wear sunscreen or other protection for their skin whenever they are exposed to sunlight: no. Journal of Primary Health Care, 2013, 5, 156-7.	0.2	0
179	WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk. PLoS Genetics, 2012, 8, e1002745.	1.5	240
180	Reply to RT Chlebowski et al. American Journal of Clinical Nutrition, 2012, 95, 259.	2.2	1

#	ARTICLE	IF	CITATIONS
181	Calcium supplements: bad for the heart?. <i>Heart</i> , 2012, 98, 895-896.	1.2	36
182	Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 929-934.	0.5	83
183	Calcium supplements and cardiovascular risk. <i>Nature Reviews Cardiology</i> , 2012, 9, 497-498.	6.1	7
184	Comment: Assessing the Potential Adverse Consequences of Supplemental Calcium on Cardiovascular Outcomes: Should We Change Our Approach to Bone Health?. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1267-1268.	0.9	0
185	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1922-1928.	1.8	50
186	Severe Vitamin D Deficiency: A Prerequisite for Chronic Obstructive Pulmonary Disease Responsiveness to Vitamin D Supplementation?. <i>Annals of Internal Medicine</i> , 2012, 156, 904.	2.0	0
187	Epidemiology and pathogenesis of osteonecrosis of the jaw. <i>Nature Reviews Rheumatology</i> , 2012, 8, 90-96.	3.5	144
188	Paget's disease of bone. <i>Clinical Biochemistry</i> , 2012, 45, 43-48.	0.8	38
189	Reprint: Paget's disease of bone. <i>Clinical Biochemistry</i> , 2012, 45, 970-975.	0.8	12
190	Pharmacotherapy of Paget's disease of bone. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 637-646.	0.9	13
191	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. <i>Nature Genetics</i> , 2012, 44, 491-501.	9.4	1,100
192	Calcium Supplements and Risk of Myocardial Infarction: An Hypothesis Twice Tested. <i>American Journal of Medicine</i> , 2012, 125, e15.	0.6	10
193	Five years of anti-resorptive activity after a single dose of zoledronate – Results from a randomized double-blind placebo-controlled trial. <i>Bone</i> , 2012, 50, 1389-1393.	1.4	83
194	Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 286-292.	1.8	43
195	Role of vitamin D deficiency in cardiovascular disease. <i>Heart</i> , 2012, 98, 609-614.	1.2	38
196	The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 243-254.	3.1	552
197	Misclassification does not explain increased cardiovascular risks of calcium supplements. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 959-959.	3.1	9
198	Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk – a perspective. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 963-974.	3.1	94

#	ARTICLE	IF	CITATIONS
199	Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1487-1493.	3.1	15
200	Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1627-1634.	3.1	109
201	Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART). <i>Clinical Endocrinology</i> , 2012, 76, 643-648.	1.2	24
202	Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 687-693.	3.1	156
203	Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1144-1149.	2.2	243
204	Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. <i>BMJ: British Medical Journal</i> , 2011, 342, d2040-d2040.	2.4	740
205	Bisphosphonates in Paget's disease. <i>Bone</i> , 2011, 49, 89-94.	1.4	37
206	Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. <i>Bone</i> , 2011, 49, 710-716.	1.4	59
207	Calcium supplementation: Balancing the cardiovascular risks. <i>Maturitas</i> , 2011, 69, 289-295.	1.0	34
208	Authors' response to editorial. <i>BMJ: British Medical Journal</i> , 2011, 342, d3520-d3520.	2.4	5
209	Characterization of and Risk Factors for the Acute-Phase Response After Zoledronic Acid. <i>Obstetrical and Gynecological Survey</i> , 2011, 66, 97-99.	0.2	1
210	Decreased bone density in men on methadone maintenance therapy. <i>Addiction</i> , 2011, 106, 349-354.	1.7	53
211	Cardiovascular effects of calcium supplementation. <i>Osteoporosis International</i> , 2011, 22, 1649-1658.	1.3	93
212	Re: The calcium scare: what would Austin Bradford Hill have thought?. <i>Osteoporosis International</i> , 2011, 22, 3079-3080.	1.3	8
213	Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. <i>Skeletal Radiology</i> , 2011, 40, 1191-1196.	1.2	33
214	Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 242-251.	3.1	220
215	Evaluation of the FRAX and Garvan fracture risk calculators in older women. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 420-427.	3.1	158
216	Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 530-537.	3.1	188

#	ARTICLE	IF	CITATIONS
217	Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 984-992.	3.1	27
218	Evidence-based policy on dietary calcium and vitamin D. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 452-454.	3.1	20
219	Calcium supplements and cardiovascular risk. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 899-899.	3.1	8
220	Skeletal phenotype of the leptin receptor-deficient mouse. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1698-1709.	3.1	98
221	A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2261-2270.	3.1	115
222	Stable Bone Density in HAART-Treated Individuals with HIV: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2721-2731.	1.8	68
223	Validation of BioDent TDI as a New Clinical Diagnostic Method. <i>Advanced Materials Research</i> , 2011, 275, 151-154.	0.3	1
224	Ghrelin is an Osteoblast Mitogen and Increases Osteoclastic Bone Resorption In Vitro. <i>International Journal of Peptides</i> , 2011, 2011, 1-7.	0.7	26
225	Bisphosphonate Therapy for Secondary Osteoporosis: Adult Perspective. <i>Hormone Research in Paediatrics</i> , 2011, 76, 28-32.	0.8	4
226	Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1091-1094.	0.5	37
227	Genome-Wide Association Study Using Extreme Truncate Selection Identifies Novel Genes Affecting Bone Mineral Density and Fracture Risk. <i>PLoS Genetics</i> , 2011, 7, e1001372.	1.5	233
228	Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 514-515.	0.2	2
229	Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 505-512.	3.1	74
230	Effects of 25-hydroxyvitamin D level and its change on parathyroid hormone in premenopausal Chinese women. <i>Osteoporosis International</i> , 2010, 21, 1935-1941.	1.3	16
231	Response to publication of PRISM trial. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 1463-1464.	3.1	9
232	Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2251-2255.	3.1	57
233	Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2256-2265.	3.1	218
234	Relationships between vascular calcification, calcium metabolism, bone density, and fractures. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2777-2785.	3.1	83

#	ARTICLE	IF	CITATIONS
235	Investigating harms in clinical trials - no easy task. International Journal of Clinical Practice, 2010, 64, 1719-1722.	0.8	1
236	Does calcium supplementation increase cardiovascular risk?. Clinical Endocrinology, 2010, 73, 689-695.	1.2	73
237	Morbidity and mortality in mild primary hyperparathyroidism. Clinical Endocrinology, 2010, 73, 688-688.	1.2	1
238	Vitamin D "let's get back to the evidence base. IBMS BoneKEy, 2010, 7, 249-253.	0.1	6
239	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. JAMA - Journal of the American Medical Association, 2010, 303, 1253.	3.8	3
240	Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1653-1662.	1.8	85
241	Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial. American Journal of Clinical Nutrition, 2010, 91, 131-139.	2.2	91
242	Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4380-4387.	1.8	206
243	Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Annals of the Rheumatic Diseases, 2010, 69, 1677-1682.	0.5	90
244	Vitamin D insufficiency and health outcomes over 5 y in older women. American Journal of Clinical Nutrition, 2010, 91, 82-89.	2.2	119
245	Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1174-1181.	1.8	285
246	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ: British Medical Journal, 2010, 341, c3691-c3691.	2.4	931
247	Evidence for anti-osteoporosis therapy in acute fracture situations"Recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Bone, 2010, 46, 267-271.	1.4	45
248	Fat and bone. Archives of Biochemistry and Biophysics, 2010, 503, 20-27.	1.4	303
249	"Cherry picking" did not occur in studied example. BMJ: British Medical Journal, 2010, 341, c5009-c5009.	2.4	3
250	Clinical Aspects of the Use of Vitamin D and Its Metabolites in Osteoporosis. , 2010, , 319-331.		0
251	Vitamin D Deficiency and Its Health Consequences in New Zealand. , 2010, , 589-601.		0
252	Calcium and bone health: position statement for the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia and the Endocrine Society of Australia. Medical Journal of Australia, 2009, 190, 316-320.	0.8	48

#	ARTICLE	IF	CITATIONS
253	Absence of Somatic SQSTM1 Mutations in Paget's Disease of Bone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 691-694.	1.8	31
254	In Vitro and in Vivo Effects of Adiponectin on Bone. <i>Endocrinology</i> , 2009, 150, 3603-3610.	1.4	190
255	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 538-544.	1.8	100
256	Actions of fibroblast growth factor-8 in bone cells in vitro. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E142-E150.	1.8	24
257	Adipose Tissue and Bone. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2009, 7, 207-209.	1.3	3
258	Adipokine Effects on Bone. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2009, 7, 240-248.	1.3	10
259	Randomized, active-controlled study of once-weekly alendronate 280mg high dose oral buffered solution for treatment of Paget's disease. <i>Osteoporosis International</i> , 2009, 20, 141-150.	1.3	7
260	Effect of calcium supplementation on hip fractures: reply to correspondence. <i>Osteoporosis International</i> , 2009, 20, 835-836.	1.3	4
261	High-dose oral vitamin D3 supplementation in the elderly. <i>Osteoporosis International</i> , 2009, 20, 1407-1415.	1.3	153
262	Calcium supplementation for older men and women?. <i>Osteoporosis International</i> , 2009, 20, 2147-2148.	1.3	2
263	Osteonecrosis of the jaw. <i>Skeletal Radiology</i> , 2009, 38, 5-9.	1.2	44
264	Is calcium supplementation a risk factor for cardiovascular diseases in older women?. <i>Nutrition Reviews</i> , 2009, 67, 424-424.	2.6	2
265	Osteonecrosis of the jaw " Who gets it, and why?. <i>Bone</i> , 2009, 44, 4-10.	1.4	243
266	Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2009, 361, 756-765.	13.9	2,747
267	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 462-463.	0.2	1
268	Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 805-807.	0.2	15
269	Time for a moratorium on vitamin D meta-analyses?. <i>BMJ: British Medical Journal</i> , 2009, 339, b4394-b4394.	2.4	15
270	Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 6-16.	3.1	189

#	ARTICLE	IF	CITATIONS
271	Relationships between fat and bone. <i>Osteoporosis International</i> , 2008, 19, 595-606.	1.3	394
272	Effect of calcium supplementation on hip fractures. <i>Osteoporosis International</i> , 2008, 19, 1119-1123.	1.3	111
273	Enhanced osteoclastogenesis in patients with tophaceous gout: Urate crystals promote osteoclast development through interactions with stromal cells. <i>Arthritis and Rheumatism</i> , 2008, 58, 1854-1865.	6.7	132
274	Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1304-1308.	3.1	41
275	Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis. , 2008, , 1659-1685.		0
276	Anti-resorptive therapies for osteoporosis. <i>Seminars in Cell and Developmental Biology</i> , 2008, 19, 473-478.	2.3	69
277	Pathogenesis and management of Paget's disease of bone. <i>Lancet, The</i> , 2008, 372, 155-163.	6.3	227
278	Calcium supplementation and vascular disease. <i>Climacteric</i> , 2008, 11, 280-286.	1.1	22
279	Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2008, 336, 262-266.	2.4	585
280	Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. <i>Journal of the American Dental Association</i> , 2008, 139, 32-40.	0.7	114
281	The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. <i>Rheumatology</i> , 2008, 48, 195-197.	0.9	26
282	Randomized Controlled Trial of Calcium Supplementation in Healthy, Nonosteoporotic, Older Men. <i>Archives of Internal Medicine</i> , 2008, 168, 2276.	4.3	122
283	Once-yearly zoledronate"an effective preventative therapy for new fractures after hip fracture?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 308-309.	2.9	0
284	Modulation of Osteoclastogenesis by Fatty Acids. <i>Endocrinology</i> , 2008, 149, 5688-5695.	1.4	115
285	Failure to Detect Measles Virus Ribonucleic Acid in Bone Cells from Patients with Paget's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1398-1401.	1.8	60
286	Artifact in the control group undermines the conclusions of a vitamin D and cancer study. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 792-792.	2.2	14
287	Does degree of baldness influence vitamin D status?. <i>Medical Journal of Australia</i> , 2008, 189, 674-675.	0.8	19
288	Calcium supplementation and cancer incidence. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 792-793.	2.2	12

#	ARTICLE	IF	CITATIONS
289	Amylin and Calcitonin Gene-Related Peptide. , 2008, , 837-853.		0
290	Pathogenesis of osteonecrosis of the jaw. IBMS BoneKEy, 2008, 5, 69-77.	0.1	2
291	Effects of beta-blockers on fracture risk. Journal of Musculoskeletal Neuronal Interactions, 2008, 8, 105-10.	0.1	22
292	The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiency. New Zealand Medical Journal, 2008, 121, 63-74.	0.5	44
293	Preptin, another peptide product of the pancreatic β -cell, is osteogenic in vitro and in vivo. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E117-E122.	1.8	74
294	Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4522-4528.	1.8	118
295	The Peroxisome Proliferator-Activated Receptor- β Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1305-1310.	1.8	399
296	Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1283-1288.	1.8	119
297	Addition of Monofluorophosphate to Estrogen Therapy in Postmenopausal Osteoporosis: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2446-2452.	1.8	21
298	Activation of Peroxisome Proliferator-Activated Receptor β (PPAR β) by Rosiglitazone Suppresses Components of the Insulin-Like Growth Factor Regulatory System in Vitro and in Vivo. Endocrinology, 2007, 148, 903-911.	1.4	130
299	The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. American Journal of Clinical Nutrition, 2007, 86, 959-964.	2.2	173
300	Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone, 2007, 41, 318-320.	1.4	332
301	Effects of calcium supplementation on bone and other end-points in normal older women " The Auckland Calcium Study. International Congress Series, 2007, 1297, 82-88.	0.2	0
302	Alteration of bone cell function by RANKL and OPG in different in vitro models. European Journal of Clinical Investigation, 2007, 37, 407-415.	1.7	24
303	Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. Clinical Endocrinology, 2007, 67, 259-264.	1.2	73
304	Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clinical Endocrinology, 2007, 67, 270-275.	1.2	49
305	Maintaining the Trust of Physicians and the Public in the Medical Literature: Report of a Task Force on Scientific Publishing of Clinical Trials. Journal of Bone and Mineral Research, 2007, 22, 1661-1667.	3.1	6
306	Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. New England Journal of Medicine, 2007, 356, 1809-1822.	13.9	2,536

#	ARTICLE	IF	CITATIONS
307	Bisphosphonates. <i>Skeletal Radiology</i> , 2007, 36, 711-714.	1.2	16
308	The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. <i>Osteoporosis International</i> , 2007, 18, 479-486.	1.3	115
309	Vitamin D sufficiency: reply to letter by Heaney. <i>Osteoporosis International</i> , 2007, 18, 835-836.	1.3	1
310	Emerging Issues With Bisphosphonates. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 691-702.	0.8	3
311	Obesity and osteoporosis. <i>Annales D'Endocrinologie</i> , 2006, 67, 125-129.	0.6	25
312	Zoledronate: Efficacy and Safety. <i>Journal of Bone and Mineral Research</i> , 2006, 21, P83-P87.	3.1	9
313	Randomized Controlled Trial of Calcium in Healthy Older Women. <i>American Journal of Medicine</i> , 2006, 119, 777-785.	0.6	249
314	Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. <i>Bone</i> , 2006, 38, 317-321.	1.4	126
315	Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. <i>Clinical Endocrinology</i> , 2006, 65, 191-197.	1.2	45
316	Long-Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate. <i>Journal of Bone and Mineral Research</i> , 2006, 22, 142-148.	3.1	132
317	Differential Gene Expression in Cultured Osteoblasts and Bone Marrow Stromal Cells From Patients With Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2006, 22, 298-309.	3.1	76
318	Bisphosphonates in pregnancy and lactation-associated osteoporosis. <i>Osteoporosis International</i> , 2006, 17, 1008-1012.	1.3	151
319	Determinants of vitamin D status in older men living in a subtropical climate. <i>Osteoporosis International</i> , 2006, 17, 1742-1748.	1.3	70
320	Imatinib Mesylate, Increased Bone Formation, and Secondary Hyperparathyroidism. <i>New England Journal of Medicine</i> , 2006, 355, 2494-2495.	13.9	59
321	Steroid-Induced Osteoporosis. , 2006, , 689-699.		0
322	Differences between the bisphosphonates for the prevention and treatment of osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 77-86.	0.9	21
323	Nutrition-Related Peptides and Bone Homeostasis. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 495-500.	3.1	67
324	Determinants of vitamin D status in older women living in a subtropical climate. <i>Osteoporosis International</i> , 2005, 16, 1641-1648.	1.3	121

#	ARTICLE	IF	CITATIONS
325	Association between Primary Hyperparathyroidism and Increased Body Weight: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1525-1530.	1.8	183
326	Effects of Calcium Supplementation on Body Weight and Blood Pressure in Normal Older Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3824-3829.	1.8	106
327	Effects of a \hat{I}^2 -Blocker on Bone Turnover in Normal Postmenopausal Women: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5212-5216.	1.8	97
328	Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial—Secondary analysis of a randomized controlled trial. <i>Bone</i> , 2005, 37, 190-191.	1.4	19
329	Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease. <i>New England Journal of Medicine</i> , 2005, 353, 898-908.	13.9	397
330	A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women. <i>Archives of Internal Medicine</i> , 2004, 164, 871.	4.3	68
331	\hat{I}^2 -Blocker Use, BMD, and Fractures in the Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 613-618.	3.1	136
332	Direct Actions of Leptin on Bone Remodeling. <i>Calcified Tissue International</i> , 2004, 74, 313-316.	1.5	23
333	Effects of Calcium Supplementation on Circulating Lipids. <i>Drugs and Aging</i> , 2004, 21, 7-17.	1.3	78
334	Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. <i>Bone</i> , 2004, 35, 224-230.	1.4	99
335	Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. <i>Biochemical and Biophysical Research Communications</i> , 2004, 318, 240-246.	1.0	47
336	Effects of Vitamin D Supplementation on Strength, Physical Performance, and Falls in Older Persons: A Systematic Review. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 1219-1226.	1.3	176
337	Bisphosphonates: new indications and methods of administration. <i>Current Opinion in Rheumatology</i> , 2003, 15, 458-463.	2.0	52
338	Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency. <i>New Zealand Medical Journal</i> , 2003, 116, U536.	0.5	19
339	Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. <i>Journal of Endocrinology</i> , 2002, 175, 405-415.	1.2	404
340	Effects of calcium supplementation on serum lipid concentrations in normal older women. <i>American Journal of Medicine</i> , 2002, 112, 343-347.	0.6	213
341	Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density. <i>New England Journal of Medicine</i> , 2002, 346, 653-661.	13.9	827
342	Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2002, 1, 93-107.	1.0	28

#	ARTICLE	IF	CITATIONS
343	Osteoporosis: non-HRT treatments. <i>Reviews in Gynaecological Practice</i> , 2002, 2, 48-53.	0.1	2
344	Relationships among body mass, its components, and bone11Published simultaneously at BoneKEy-Osteovision (http://www.bonekey-ibms.org), a Web site sponsored by the International Bone and Mineral Society.. <i>Bone</i> , 2002, 31, 547-555.	1.4	551
345	Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. <i>Clinical Endocrinology</i> , 2002, 56, 703-711.	1.2	78
346	A new receptor to turn on bone growth. <i>New Zealand Medical Journal</i> , 2002, 115, 169-70.	0.5	0
347	Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. <i>Bone</i> , 2001, 29, 162-168.	1.4	149
348	Effect of pravastatin on frequency of fracture in the LIPID study: secondly analysis of a randomised controlled trial. <i>Lancet, The</i> , 2001, 357, 509-512.	6.3	227
349	Determinants of sex hormone-binding globulin in normal postmenopausal women. <i>Clinical Endocrinology</i> , 2001, 54, 81-87.	1.2	40
350	Lysophosphatidic Acid Is an Osteoblast Mitogen Whose Proliferative Actions Involve Gi Proteins and Protein Kinase C, But Not P42/44 Mitogen-Activated Protein Kinases*. <i>Endocrinology</i> , 2001, 142, 1098-1106.	1.4	57
351	Lysophosphatidic Acid Is an Osteoblast Mitogen Whose Proliferative Actions Involve Gi Proteins and Protein Kinase C, But Not P42/44 Mitogen-Activated Protein Kinases. <i>Endocrinology</i> , 2001, 142, 1098-1106.	1.4	18
352	A Potential Role for Adrenomedullin as a Local Regulator of Bone Growth. <i>Endocrinology</i> , 2001, 142, 1849-1857.	1.4	15
353	Effects of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women With Primary Hyperparathyroidism. <i>Archives of Internal Medicine</i> , 2000, 160, 2161.	4.3	78
354	Preventing glucocorticoid-induced osteoporosis. <i>Zeitschrift Fur Rheumatologie</i> , 2000, 59, 1197-11102.	0.5	7
355	Calcium Supplements and Nail Quality. <i>New England Journal of Medicine</i> , 2000, 343, 1817-1817.	13.9	8
356	Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. <i>American Journal of Medicine</i> , 2000, 109, 362-370.	0.6	170
357	Hormone Replacement Therapy Causes a Respiratory Alkalosis in Normal Postmenopausal Women1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1997-2001.	1.8	22
358	Stimulation of Osteoblast Proliferation by C-Terminal Fragments of Parathyroid Hormone-Related Protein. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 915-922.	3.1	76
359	Pharmacological Management of Osteoporosis in Postmenopausal Women. <i>Drugs and Aging</i> , 1999, 15, 349-363.	1.3	12
360	The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. <i>Clinical Endocrinology</i> , 1998, 49, 615-618.	1.2	88

#	ARTICLE	IF	CITATIONS
361	Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 275, E694-E699.	1.8	60
362	Parathyroid Hormone-Related Protein-(107-139) Inhibits Bone Resorption in Vivo*. <i>Endocrinology</i> , 1997, 138, 1299-1304.	1.4	104
363	Premature Hair Graying and Bone Mineral Density1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3580-3583.	1.8	29
364	Glucocorticoid osteoporosis--mechanisms and management. <i>European Journal of Endocrinology</i> , 1997, 137, 209-217.	1.9	238
365	Osteoporosis -emerging consensus. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 643-647.	0.5	8
366	Steroid-induced osteoporosis. <i>Osteoporosis International</i> , 1997, 7, 213-216.	1.3	28
367	Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis. <i>Clinical Endocrinology</i> , 1997, 46, 87-92.	1.2	26
368	Parathyroid Hormone-Related Protein-(107-139) Inhibits Bone Resorption in Vivo. <i>Endocrinology</i> , 1997, 138, 1299-1304.	1.4	28
369	Establishing healthy bones in the young. <i>Australian Family Physician</i> , 1997, 26, 132-4.	0.5	0
370	Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. <i>American Journal of Medicine</i> , 1996, 101, 341-348.	0.6	164
371	Insulin increases histomorphometric indices of bone formation In vivo. <i>Calcified Tissue International</i> , 1996, 59, 492-495.	1.5	134
372	Effect of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women with Mild Primary Hyperparathyroidism. <i>Annals of Internal Medicine</i> , 1996, 125, 360.	2.0	159
373	Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. <i>Clinical Endocrinology</i> , 1996, 44, 293-296.	1.2	44
374	Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism. <i>Clinical Endocrinology</i> , 1996, 44, 696-702.	1.2	48
375	Testosterone Therapy in Glucocorticoid-Treated Men. <i>Archives of Internal Medicine</i> , 1996, 156, 1173.	4.3	290
376	Insulin Increases Histomorphometric Indices of Bone Formation In Vivo. <i>Calcified Tissue International</i> , 1996, 59, 492-495.	1.5	43
377	Testosterone therapy in glucocorticoid-treated men. <i>Archives of Internal Medicine</i> , 1996, 156, 1173-7.	4.3	43
378	Longer femoral necks in the young: a predictor of further increases in hip fracture incidence?. <i>New Zealand Medical Journal</i> , 1996, 109, 234-5.	0.5	3

#	ARTICLE	IF	CITATIONS
379	Osteoporosis Research in Auckland. <i>Clinical Science</i> , 1995, 88, 12-14.	1.8	0
380	Ototoxicity associated with intravenous bisphosphonate administration. <i>Calcified Tissue International</i> , 1995, 56, 584-585.	1.5	28
381	Regular exercise dissociates fat mass and bone density in premenopausal women.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 1764-1768.	1.8	77
382	Amylin Stimulates Osteoblast Proliferation and Increases Mineralized Bone Volume in Adult Mice. <i>Biochemical and Biophysical Research Communications</i> , 1995, 207, 133-139.	1.0	116
383	The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. <i>American Journal of Medicine</i> , 1995, 99, 636-641.	0.6	144
384	Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial. <i>American Journal of Medicine</i> , 1995, 98, 331-335.	0.6	410
385	Regular exercise dissociates fat mass and bone density in premenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 1764-1768.	1.8	63
386	Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. <i>Archives of Internal Medicine</i> , 1995, 155, 1813-5.	4.3	8
387	Body Weight and Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism. <i>Annals of Internal Medicine</i> , 1994, 121, 745.	2.0	92
388	Determinants of the rate of bone loss in normal postmenopausal women.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 950-954.	1.8	124
389	Benefits, Risks and Costs of Calcium Supplementation in Postmenopausal Women. <i>Pharmacoeconomics</i> , 1994, 5, 1-4.	1.7	3
390	Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1595-1599.	1.8	114
391	Glucocorticoid Osteoporosis. <i>Journal of Asthma</i> , 1994, 31, 7-18.	0.9	52
392	Volumetric bone density of the lumbar spine is related to fat mass but not lean mass in normal postmenopausal women. <i>Osteoporosis International</i> , 1994, 4, 362-367.	1.3	105
393	The investigation of hypercalcaemia. <i>Clinical Endocrinology</i> , 1994, 41, 405-406.	1.2	3
394	Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. <i>Clinical Endocrinology</i> , 1994, 40, 671-677.	1.2	85
395	Relation between increase in length of hip axis in older women between 1950s and 1990s and increase in age specific rates of hip fracture. <i>BMJ: British Medical Journal</i> , 1994, 309, 508-509.	2.4	82
396	Determinants of the rate of bone loss in normal postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 950-954.	1.8	104

#	ARTICLE	IF	CITATIONS
397	Steroid osteoporosis. <i>Osteoporosis International</i> , 1993, 3, 144-146.	1.3	6
398	Effect of Calcium Supplementation on Bone Loss in Postmenopausal Women. <i>New England Journal of Medicine</i> , 1993, 328, 460-464.	13.9	495
399	Circulating insulin levels are related to bone density in normal postmenopausal women. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1993, 265, E655-E659.	1.8	103
400	The effect of leukemia inhibitory factor on bone in vivo. <i>Endocrinology</i> , 1993, 132, 1359-1366.	1.4	27
401	Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 75, 779-782.	1.8	311
402	Determinants of total body and regional bone mineral density in normal postmenopausal women—a key role for fat mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 75, 45-51.	1.8	367
403	Relationships between upper-arm anthropometry and soft-tissue composition in postmenopausal women. <i>American Journal of Clinical Nutrition</i> , 1992, 56, 463-466.	2.2	22
404	Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. <i>Osteoporosis International</i> , 1992, 2, 103-105.	1.3	85
405	Normal bone mineral density following cure of Cushing's syndrome. <i>Clinical Endocrinology</i> , 1992, 36, 229-234.	1.2	134
406	Postpregnancy osteoporosis associated with hypercalcaemia. <i>Clinical Endocrinology</i> , 1992, 37, 298-303.	1.2	74
407	Lateral spine densitometry is a more sensitive indicator of glucocorticoid-induced bone loss. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 1221-1225.	3.1	97
408	Determinants of total body and regional bone mineral density in normal postmenopausal women—a key role for fat mass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 75, 45-51.	1.8	348
409	Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 75, 779-782.	1.8	276
410	Bone density in women receiving depot medroxyprogesterone acetate for contraception. <i>BMJ: British Medical Journal</i> , 1991, 303, 13-16.	2.4	229
411	The Influence of Osteophytes and Aortic Calcification on Spinal Mineral Density in Postmenopausal Women*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 1372-1374.	1.8	208
412	Adenylate cyclase blockers dissociate PTH-stimulated bone resorption from cAMP production. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1990, 258, E708-E714.	1.8	10
413	Calcitropic Hormone Levels in Polynesians: Evidence against Their Role in Interracial Differences in Bone Mass*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 1452-1456.	1.8	30
414	Prevention of glucocorticoid-induced osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 619-623.	3.1	53

#	ARTICLE	IF	CITATIONS
415	Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Archives of Internal Medicine, 1990, 150, 2545-8.	4.3	31
416	Steroid osteoporosis. Calcified Tissue International, 1989, 45, 63-67.	1.5	47
417	INSULIN-LIKE GROWTH FACTOR 1 AND BONE TURNOVER IN GLUCOCORTICOID-TREATED AND CONTROL SUBJECTS. Clinical Endocrinology, 1989, 30, 347-353.	1.2	19
418	PATHOGENESIS AND TREATMENT OF STEROID OSTEOPOROSIS. Clinical Endocrinology, 1989, 30, 83-103.	1.2	178
419	The role of dietary calcium in the pathogenesis and treatment of osteoporosis. New Zealand Medical Journal, 1989, 102, 532-3.	0.5	1
420	PREVENTION OF STEROID-INDUCED OSTEOPOROSIS WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (APD). Lancet, The, 1988, 331, 143-146.	6.3	305
421	TWO-YEAR FOLLOW-UP OF BIPHOSPHONATE (APD) TREATMENT IN STEROID OSTEOPOROSIS. Lancet, The, 1988, 332, 1144.	6.3	57
422	Evidence for Decreased Tubular Reabsorption of Calcium in Glucocorticoid-Treated Asthmatics. Hormone Research, 1987, 27, 200-204.	1.8	95
423	THE ACUTE BIOCHEMICAL EFFECTS OF FOUR PROPRIETARY CALCIUM PREPARATIONS. Australian and New Zealand Journal of Medicine, 1986, 16, 193-197.	0.5	99